Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.

Leotta S, Pirosa MC, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MA, Martino EA, Curto Pelle A, Leotta V, Milone G, Cupri A, Vaddinelli D, Villari L, Conticello C, Milone G.

Chemotherapy. 2019;64(2):110-114. doi: 10.1159/000502473. Epub 2019 Sep 18.

PMID:
31533095
2.

CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allotransplanted Patients.

Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, Pierini A, Bernardi S, Morello E, Polverelli N, Turra A, Cattina F, Gandolfi L, Rambaldi B, Lorentino F, Serio F, Milone G, Velardi A, Foà R, Ciceri F, Russo D, Peccatori J.

Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019048. doi: 10.4084/MJHID.2019.048. eCollection 2019.

3.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24.

PMID:
31339826
4.

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo.

Derenzini E, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1387-1394. doi: 10.1016/j.bbmt.2019.03.026. Epub 2019 Mar 30.

PMID:
30935966
5.

PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.

Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, Milone G, Cerutti I, Zabaljauregui S, Mariano R, Grecco HF, Basquiera AL, Saba S, Rudoy S, Sackmann F, Castano V, Remaggi G, Cabrejo M, Roveri E, Casale MF, Cabane V, Taus R, Venturini C, Sakamoto F, Varela AI, Riddick M, Pavlovsky S; Grupo Argentino de tratamiento de Leucemia Aguda (GATLA), Argentina.

Br J Haematol. 2019 Jun;185(5):865-873. doi: 10.1111/bjh.15838. Epub 2019 Mar 12.

PMID:
30864146
6.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.

Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

PMID:
30709437
7.

B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.

Stella S, Massimino M, Tirrò E, Vitale SR, Scalise L, Leotta S, Pennisi MS, Puma A, Romano C, Stagno F, Sapienza G, Milone G, Manzella L.

Anticancer Res. 2019 Jan;39(1):431-435. doi: 10.21873/anticanres.13130.

PMID:
30591491
8.

Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.

Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianti di Midollo Osseo. (GITMO).

Biol Blood Marrow Transplant. 2019 May;25(5):932-940. doi: 10.1016/j.bbmt.2018.12.064. Epub 2018 Dec 20.

PMID:
30579966
9.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

10.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
11.

Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.

Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A.

Bone Marrow Transplant. 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12.

12.

Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.

Milone G, Sacchi N, Gallina A, Leotta S, Picardi A, Guidi S, Tripepi G, Rambaldi A, Bonifazi F.

Bone Marrow Transplant. 2018 Mar;53(3):291-299. doi: 10.1038/s41409-017-0026-z. Epub 2017 Dec 21.

PMID:
29269809
13.

'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Giaccone L, Mancini G, Mordini N, Gargiulo G, De Cecco V, Angelini S, Arpinati M, Baronciani D, Bozzoli V, Bramanti S, Calore E, Cavattoni IM, Cimminiello M, Colombo AA, Facchini L, Falcioni S, Faraci M, Fedele R, Guidi S, Iori AP, Marotta S, Micò MC, Milone G, Onida F, Pastore D, Patriarca F, Pini M, Raimondi R, Rovelli A, Santarone S, Severino A, Skert C, Stanghellini MTL, Tecchio C, Vassallo E, Chiarucci M, Bruno B, Bonifazi F, Olivieri A.

Bone Marrow Transplant. 2018 Jan;53(1):58-63. doi: 10.1038/bmt.2017.223. Epub 2017 Oct 30.

14.

Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey.

Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI).

Clin Infect Dis. 2017 Nov 13;65(11):1884-1896. doi: 10.1093/cid/cix690.

15.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

16.

Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.

Milone G, Martino M, Leotta S, Spadaro A, Zammit V, Cupri A, Avola G, Camuglia MG, Di Marco A, Scalzulli P, Morelli M, Olivieri A, Tripepi G.

Leuk Lymphoma. 2018 Jan;59(1):42-48. doi: 10.1080/10428194.2017.1324161. Epub 2017 Jun 2.

PMID:
28573902
17.

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.

Castagna L, Mussetti A, Devillier R, Dominietto A, Marcatti M, Milone G, Maura F, de Philippis C, Bruno B, Furst S, Blaise D, Corradini P, Montefusco V.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1549-1554. doi: 10.1016/j.bbmt.2017.05.006. Epub 2017 May 10.

18.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5.

19.

Antitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinase.

Fichera GA, Fichera M, Milone G.

Anticancer Drugs. 2016 Aug;27(7):609-19. doi: 10.1097/CAD.0000000000000367.

20.

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Martino M, Lemoli RM, Girmenia C, Castagna L, Bruno B, Cavallo F, Offidani M, Scortechini I, Montanari M, Milone G, Postacchini L, Olivieri A.

Bone Marrow Transplant. 2016 Aug;51(8):1032-40. doi: 10.1038/bmt.2016.79. Epub 2016 Apr 4. Review.

21.

Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.

Bramanti S, Nocco A, Mauro E, Milone G, Morabito L, Sarina B, Crocchiolo R, Timofeeva I, Capizzuto R, Carlo-Stella C, Santoro A, Castagna L.

Transfusion. 2016 May;56(5):1096-1100. doi: 10.1111/trf.13523. Epub 2016 Mar 28.

PMID:
27021516
22.

Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.

Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, Kanda Y, Miyamura K, Murata M, Fukuda T, Sakamaki H, Kimura F, Seo S, Aljurf M, Yoshimi A, Milone G, Wood WA, Ustun C, Hashimi S, Pasquini M, Bonfim C, Dalal J, Hahn T, Atsuta Y, Saber W.

Biol Blood Marrow Transplant. 2016 Apr;22(4):744-751. doi: 10.1016/j.bbmt.2015.12.027. Epub 2016 Jan 4.

23.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F.

N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.

24.

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.

Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A.

Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.

25.

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.

Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I.

Ann Hematol. 2015 Nov;94(11):1875-83. doi: 10.1007/s00277-015-2462-4. Epub 2015 Jul 31.

26.

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.

Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantuono G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M.

Stem Cell Res Ther. 2015 Apr 17;6:64. doi: 10.1186/s13287-015-0033-1.

27.

Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.

Horstmann K, Boumendil A, Finke J, Finel H, Kanfer E, Milone G, Russell N, Bacigalupo A, Chalandon Y, Diez-Martin JL, Ifrah N, Chacon MJ, Dreger P.

Bone Marrow Transplant. 2015 Jun;50(6):790-4. doi: 10.1038/bmt.2015.12. Epub 2015 Mar 9.

PMID:
25751644
28.

Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment.

Milone G, Camuglia MG, Avola G, Di Marco A, Leotta S, Cupri A, Spina P, Romano A, Spina E, Azzaro MP, Berritta D, Parisi M, Tripepi G.

Exp Hematol. 2015 Jun;43(6):430-8.e1. doi: 10.1016/j.exphem.2015.02.002. Epub 2015 Feb 20.

PMID:
25704053
29.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.

Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee.

Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.

PMID:
25621805
30.

Quality assessment of autologous haematopoietic blood progenitor cell grafting.

Lanza F, Dallorso S, Milone G, Spedini P, Viganò C, Johnsen H.

Ann Hematol. 2015 Apr;94(4):705-6. doi: 10.1007/s00277-014-2235-5. Epub 2014 Oct 16. No abstract available.

PMID:
25318761
31.

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.

Milone G, Leotta S, Cupri A, Fauci AL, Spina P, Parisi M, Berritta D, Tripepi G.

Bone Marrow Transplant. 2014 Sep;49(9):1193-7. doi: 10.1038/bmt.2014.140. Epub 2014 Jul 7.

PMID:
25000456
32.

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.

Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, Specchia G, Fanci R, Luppi M, Cudillo L, Cantaffa R, Milone G, Bocchia M, Martinelli G, Offidani M, Chierichini A, Fabbiano F, Quarta G, Primon V, Martino B, Manna A, Zuffa E, Ferrari A, Gentile G, Foà R, Del Favero A.

J Clin Oncol. 2014 May 10;32(14):1463-71. doi: 10.1200/JCO.2013.51.6963. Epub 2014 Apr 14.

PMID:
24733807
33.

Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.

Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S, Marktel S, Cimminiello M, Messina G, Irrera G, Offidani M, Console G, Castagna L, Milone G, Bruno B, Tripepi G, Lemoli RM, Olivieri A; Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) – Sezione Trapianto Autologo.

Biol Blood Marrow Transplant. 2014 Jul;20(7):1026-32. doi: 10.1016/j.bbmt.2014.03.027. Epub 2014 Mar 31.

34.

Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, Pecoraro C, Guidi S, Iori AP, Montante B, Chiusolo P, Lanino E, Carella AM, Zucchetti E, Bruno B, Irrera G, Patriarca F, Baronciani D, Musso M, Prete A, Risitano AM, Russo D, Mordini N, Pastore D, Vacca A, Onida F, Falcioni S, Pisapia G, Milone G, Vallisa D, Olivieri A, Bonini A, Castagnola E, Sica S, Majolino I, Bosi A, Busca A, Arcese W, Bandini G, Bacigalupo A, Rambaldi A, Locasciulli A.

Biol Blood Marrow Transplant. 2014 Jun;20(6):872-80. doi: 10.1016/j.bbmt.2014.03.004. Epub 2014 Mar 14.

35.

Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.

Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, Delia M, Nosari A, Bonini A, Cattaneo C, Melillo L, Caramatti C, Milone G, Scime' R, Picardi M, Fanin R, Pagano L; SEIFEM GROUP (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne).

Mycoses. 2014 Jun;57(6):342-50. doi: 10.1111/myc.12161. Epub 2013 Dec 23.

PMID:
24373120
36.

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Labopin M, Gorin NC, Polge E, Socié G, Gurman G, Gluckman E, Jindra P, Poiré X, Schäfer-Eckart K, Ruutu T, Milone G, Arcese W, Mohty M, Rocha V; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2014 Mar;49(3):376-81. doi: 10.1038/bmt.2013.178. Epub 2013 Nov 18.

PMID:
24241579
37.

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.

Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21.

PMID:
24138497
38.

Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.

Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE; Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1670-6. doi: 10.1016/j.bbmt.2013.08.005. Epub 2013 Aug 27. Review.

39.

The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.

Pierelli L, Berto P, Accorsi P, Milone G, Lopatriello S, Aiello A, Iacopino P, Olivieri A, Rambaldi A, Bosi A.

Transfus Apher Sci. 2013 Dec;49(3):615-22. doi: 10.1016/j.transci.2013.07.025. Epub 2013 Aug 6.

PMID:
23973731
40.

Algorithms for early identification of poor mobilization and for on-demand use of plerixafor in patients mobilized by chemotherapy and granulocyte-colony stimulating factor.

Milone G, Tripepi G.

Leuk Lymphoma. 2014 Mar;55(3):725-6. doi: 10.3109/10428194.2013.832243. Epub 2013 Sep 3. No abstract available.

PMID:
23927398
41.

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.

Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A.

Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Erratum in: Transfusion. 2014 Jun;54(6):1688-91.

PMID:
23781769
42.

In AML patients treated by allogeneic hematopoietic transplantation, CD34+ supermobilization is a negative prognostic factor.

Avola G, Camuglia MG, Milone G.

Leuk Res. 2013 Jul;37(7):853-4. doi: 10.1016/j.leukres.2013.03.015. Epub 2013 Apr 22. No abstract available.

PMID:
23618688
43.

Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.

Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B.

Biol Blood Marrow Transplant. 2013 Jun;19(6):940-8. doi: 10.1016/j.bbmt.2013.03.012. Epub 2013 Mar 26.

44.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.

PMID:
23482933
45.

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.

Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties.

Blood. 2013 Jan 17;121(3):440-6. doi: 10.1182/blood-2012-08-448613. Epub 2012 Nov 30.

PMID:
23203822
46.

Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A.

Blood Transfus. 2013 Jan;11(1):94-101. doi: 10.2450/2012.0004-12. Epub 2012 Oct 10.

47.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.

Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.

48.

Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program.

Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G, Offidani M, Scortechini I, Moscato T, Fedele R, Milone G, Castagna L, Olivieri A.

Expert Opin Biol Ther. 2012 Nov;12(11):1449-62. doi: 10.1517/14712598.2012.707185. Epub 2012 Jul 13. Review.

PMID:
22788745
49.

Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.

Alejandre ME, Pavlovsky MA, Remaggi G, Corrado C, Fernandez I, Milone G, Pavlovsky A, Madalena L, Pandolfo M, Facio ML, Bresciani P, Pavlovsky S, Pizzolato MA.

Clin Chem Lab Med. 2012 Apr 24;50(6):1093-7. doi: 10.1515/cclm-2011-0544.

PMID:
22706252
50.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.

J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. J Clin Oncol. 2014 Apr 20;32(12):1285.

PMID:
22585692

Supplemental Content

Loading ...
Support Center